Literature DB >> 21199897

Cutting edge: TIGIT has T cell-intrinsic inhibitory functions.

Nicole Joller1, Jason P Hafler, Boel Brynedal, Nasim Kassam, Silvia Spoerl, Steven D Levin, Arlene H Sharpe, Vijay K Kuchroo.   

Abstract

Costimulatory molecules regulate the functional outcome of T cell activation, and disturbance of the balance between activating and inhibitory signals results in increased susceptibility to infection or the induction of autoimmunity. Similar to the well-characterized CD28/CTLA-4 costimulatory pathway, a newly emerging pathway consisting of CD226 and T cell Ig and ITIM domain (TIGIT) has been associated with susceptibility to multiple autoimmune diseases. In this study, we examined the role of the putative coinhibitory molecule TIGIT and show that loss of TIGIT in mice results in hyperproliferative T cell responses and increased susceptibility to autoimmunity. TIGIT is thought to indirectly inhibit T cell responses by the induction of tolerogenic dendritic cells. By generating an agonistic anti-TIGIT Ab, we demonstrate that TIGIT can inhibit T cell responses directly independent of APCs. Microarray analysis of T cells stimulated with agonistic anti-TIGIT Ab revealed that TIGIT can act directly on T cells by attenuating TCR-driven activation signals.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21199897      PMCID: PMC3128994          DOI: 10.4049/jimmunol.1003081

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  CD226 is specifically expressed on the surface of Th1 cells and regulates their expansion and effector functions.

Authors:  Valerie Dardalhon; Anna S Schubart; Jayagopala Reddy; Jennifer Hartt Meyers; Laurent Monney; Catherine A Sabatos; Rakesh Ahuja; Khuong Nguyen; Gordon J Freeman; Edward A Greenfield; Raymond A Sobel; Vijay K Kuchroo
Journal:  J Immunol       Date:  2005-08-01       Impact factor: 5.422

2.  Linear models and empirical bayes methods for assessing differential expression in microarray experiments.

Authors:  Gordon K Smyth
Journal:  Stat Appl Genet Mol Biol       Date:  2004-02-12

3.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

4.  CTLA-4 blockade: therapeutic potential in cancer treatments.

Authors:  Ahmad A Tarhini; Fatima Iqbal
Journal:  Onco Targets Ther       Date:  2010-06-24       Impact factor: 4.147

5.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.

Authors:  E A Tivol; F Borriello; A N Schweitzer; W P Lynch; J A Bluestone; A H Sharpe
Journal:  Immunity       Date:  1995-11       Impact factor: 31.745

6.  The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells.

Authors:  Xin Yu; Kristin Harden; Lino C Gonzalez; Michelle Francesco; Eugene Chiang; Bryan Irving; Irene Tom; Sinisa Ivelja; Canio J Refino; Hilary Clark; Dan Eaton; Jane L Grogan
Journal:  Nat Immunol       Date:  2008-11-16       Impact factor: 25.606

7.  Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112).

Authors:  Satoko Tahara-Hanaoka; Kazuko Shibuya; Yuko Onoda; Hua Zhang; Satoshi Yamazaki; Akitomo Miyamoto; Shin-Ichiro Honda; Lewis L Lanier; Akira Shibuya
Journal:  Int Immunol       Date:  2004-04       Impact factor: 4.823

8.  PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes.

Authors:  Vamsi K Mootha; Cecilia M Lindgren; Karl-Fredrik Eriksson; Aravind Subramanian; Smita Sihag; Joseph Lehar; Pere Puigserver; Emma Carlsson; Martin Ridderstråle; Esa Laurila; Nicholas Houstis; Mark J Daly; Nick Patterson; Jill P Mesirov; Todd R Golub; Pablo Tamayo; Bruce Spiegelman; Eric S Lander; Joel N Hirschhorn; David Altshuler; Leif C Groop
Journal:  Nat Genet       Date:  2003-07       Impact factor: 38.330

9.  CD226 Gly307Ser association with multiple autoimmune diseases.

Authors:  J P Hafler; L M Maier; J D Cooper; V Plagnol; A Hinks; M J Simmonds; H E Stevens; N M Walker; B Healy; J M M Howson; M Maisuria; S Duley; G Coleman; S C L Gough; J Worthington; V K Kuchroo; L S Wicker; J A Todd
Journal:  Genes Immun       Date:  2008-10-30       Impact factor: 2.676

10.  Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate.

Authors:  M Schiff; M Keiserman; C Codding; S Songcharoen; A Berman; S Nayiager; C Saldate; T Li; R Aranda; J-C Becker; C Lin; P L N Cornet; M Dougados
Journal:  Ann Rheum Dis       Date:  2007-11-29       Impact factor: 19.103

View more
  191 in total

Review 1.  Cell surface signaling molecules in the control of immune responses: a tide model.

Authors:  Yuwen Zhu; Sheng Yao; Lieping Chen
Journal:  Immunity       Date:  2011-04-22       Impact factor: 31.745

2.  Immune Regulation of sickle Cell Alloimmunization.

Authors:  Karina Yazdanbakhsh; Beth H Shaz; Christopher D Hillyer
Journal:  ISBT Sci Ser       Date:  2016-11-15

3.  Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell-cell adhesion and signaling mechanism that requires cis-trans receptor clustering.

Authors:  Katharina F Stengel; Kristin Harden-Bowles; Xin Yu; Lionel Rouge; Jianping Yin; Laëtitia Comps-Agrar; Christian Wiesmann; J Fernando Bazan; Dan L Eaton; Jane L Grogan
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-15       Impact factor: 11.205

Review 4.  Multiple sclerosis.

Authors:  Alyssa Nylander; David A Hafler
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

Review 5.  Immune checkpoints in central nervous system autoimmunity.

Authors:  Nicole Joller; Anneli Peters; Ana C Anderson; Vijay K Kuchroo
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

6.  T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.

Authors:  Sarah E Josefsson; Kanutte Huse; Arne Kolstad; Klaus Beiske; Daniela Pende; Chloé B Steen; Else Marit Inderberg; Ole Christian Lingjærde; Bjørn Østenstad; Erlend B Smeland; Ronald Levy; Jonathan M Irish; June H Myklebust
Journal:  Clin Cancer Res       Date:  2017-12-07       Impact factor: 12.531

7.  Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells.

Authors:  Veronika Bachanova; Dhifaf Sarhan; Todd E DeFor; Sarah Cooley; Angela Panoskaltsis-Mortari; Bruce R Blazar; Julie M Curtsinger; Linda Burns; Daniel J Weisdorf; Jeffrey S Miller
Journal:  Cancer Immunol Immunother       Date:  2017-12-07       Impact factor: 6.968

8.  Exosomes Represent an Immune Suppressive T Cell Checkpoint in Human Chronic Inflammatory Microenvironments.

Authors:  Gautam N Shenoy; Maulasri Bhatta; Jenni L Loyall; Raymond J Kelleher; Joel M Bernstein; Richard B Bankert
Journal:  Immunol Invest       Date:  2020-04-17       Impact factor: 3.657

9.  T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-γ production of natural killer cells via β-arrestin 2-mediated negative signaling.

Authors:  Man Li; Pengyan Xia; Ying Du; Shengwu Liu; Guanling Huang; Jun Chen; Honglian Zhang; Ning Hou; Xuan Cheng; Luyu Zhou; Peifeng Li; Xiao Yang; Zusen Fan
Journal:  J Biol Chem       Date:  2014-05-09       Impact factor: 5.157

Review 10.  Targeting PVR (CD155) and its receptors in anti-tumor therapy.

Authors:  Paola Kučan Brlić; Tihana Lenac Roviš; Guy Cinamon; Pini Tsukerman; Ofer Mandelboim; Stipan Jonjić
Journal:  Cell Mol Immunol       Date:  2018-10-01       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.